Tumor-Infiltration Mimicking Model of Contaminated Ovarian Tissue as an Innovative Platform for Advanced Cancer Research

被引:0
|
作者
Moghassemi, Saeid [1 ]
Dadashzadeh, Arezoo [1 ]
Lucci, Carolina M. [2 ]
Amorim, Christiani A. [1 ]
机构
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Pole Rech Physiopathol Reprod, Ave Hippocrate 54,Bte B1 55-03, B-1200 Brussels, Belgium
[2] Univ Brasilia, Inst Biol Sci, Dept Physiol Sci, Brasilia, Brazil
来源
AAPS JOURNAL | 2024年 / 27卷 / 01期
关键词
3D scaffold; hydrogel; PEGylated Fibrin; tissue engineering; tumor model; MESENCHYMAL STEM-CELLS; ACUTE MYELOID-LEUKEMIA; 3D; HYDROGEL; MICROENVIRONMENT;
D O I
10.1208/s12248-024-00997-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The development of advanced preclinical models is crucial for the evaluation and validation of novel therapeutic strategies in oncology. Three-dimensional (3D) microtumor models, which incorporate both cancer and stromal cells within biomimetic hydrogels, have emerged as powerful tools that more accurately replicate the complex tumor microenvironment compared to traditional two-dimensional (2D) cell culture systems. In this context, our study aims to develop 3D microtumor models by integrating cancer and stromal cells within an extracellular-matrix-mimetic hydrogel, as a physiologically accurate microtumor model that can serve as an innovative platform for advanced cancer research and drug screening. Microtumors composed of varying ratios of leukemia cells (HL-60) to healthy ovarian stromal cells (SCs) (1:1, 1:10, 1:100, or 1:1000) were encapsulated in PEGylated fibrin hydrogel and cultured for 5 days. The proliferation and dynamics of cancerous and healthy cell populations were evaluated using CD43/Ki67 immunofluorescence double staining. Our findings indicate that tumor development and malignancy progression can be influenced by adjusting cell culture ratios and incubation time. Notably, the HL-60:SCs ratio of 1:100 closely replicated leukemia cell invasion in ovarian tissue, demonstrating detectable malignancy on the third and fifth days without significant changes in total cell density dynamics. This 3D leukemia microtumor model offers superior physiological relevance compared to traditional 2D in vitro assays and shows promising potential for applications in cellular analysis and drug screening.
引用
收藏
页数:10
相关论文
共 31 条
  • [21] Chick Embryo Experimental Platform for Micrometastases Research in a 3D Tissue Engineering Model: Cancer Biology, Drug Development, and Nanotechnology Applications
    Guller, Anna
    Kuschnerus, Inga
    Rozova, Vlada
    Nadort, Annemarie
    Yao, Yin
    Khabir, Zahra
    Garcia-Bennett, Alfonso
    Liang, Liuen
    Polikarpova, Aleksandra
    Qian, Yi
    Goldys, Ewa M.
    Zvyagin, Andrei V.
    BIOMEDICINES, 2021, 9 (11)
  • [22] Characterization of kallikrein-related peptidase 4 (KLK4) mRNA expression in tumor tissue of advanced high-grade serous ovarian cancer patients
    Gong, Weiwei
    Liu, Yueyang
    Seidl, Christof
    Dreyer, Tobias
    Drecoll, Enken
    Kotzsch, Matthias
    Bronger, Holger
    Dorn, Julia
    Magdolen, Viktor
    PLOS ONE, 2019, 14 (02):
  • [23] Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients' prognosis
    Dettmar, Larissa
    Ahmed, Nancy
    Kotzsch, Matthias
    Diersch, Sandra
    Napieralski, Rudolf
    Darmoul, Dalila
    Schmitt, Manfred
    Weichert, Wilko
    Kiechle, Marion
    Dorn, Julia
    Magdolen, Viktor
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2018, 144 (06) : 1109 - 1118
  • [24] Advanced high-grade serous ovarian cancer: inverse association of KLK13 and KLK14 mRNA levels in tumor tissue and patients’ prognosis
    Larissa Dettmar
    Nancy Ahmed
    Matthias Kotzsch
    Sandra Diersch
    Rudolf Napieralski
    Dalila Darmoul
    Manfred Schmitt
    Wilko Weichert
    Marion Kiechle
    Julia Dorn
    Viktor Magdolen
    Journal of Cancer Research and Clinical Oncology, 2018, 144 : 1109 - 1118
  • [25] Assessment of kallikrein-related peptidase 5 (KLK5) protein expression in tumor tissue of advanced ovarian cancer patients by immunohistochemistry and ELISA: correlation with clinical outcome
    Dorn, Julia
    Yassouridis, Alexandra
    Walch, Axel
    Diamandis, Eleftherios P.
    Schmitt, Manfred
    Kiechle, Marion
    Wang, Ping
    Drecoll, Enken
    Schmalfeldt, Barbara
    Loessner, Daniela
    Kotzsch, Matthias
    Magdolen, Viktor
    AMERICAN JOURNAL OF CANCER RESEARCH, 2016, 6 (01): : 61 - 70
  • [26] Human cancer xenografts in immunocompromised mice provide an advanced genuine tumor model for research and drug development-A revisit of murine models for human cancers
    Yang, Quan-en
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2021, 1865 (08):
  • [27] DPX-Survivac and intermittent low-dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression.
    Tanyi, Janos Laszlo
    Dorigo, Oliver
    Oza, Amit M.
    Strauss, James Fredric
    Pejovic, Tanja
    Ghamande, Sharad A.
    Ghatage, Prafull
    Villella, Jeannine A.
    Fiset, Stephan
    MacDonald, Lisa Diana
    Hrytsenko, Olga
    Stanford, Marianne
    Newton, Robert C.
    Leopold, Lance
    Rosu, Gabriela Nicola
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [28] Elevated tumor tissue protein expression levels of kallikrein-related peptidases KLK10 and KLK11 are associated with a better prognosis in advanced high-grade serous ovarian cancer patients
    Geng, Xiaocong
    Liu, Yueyang
    Dreyer, Tobias
    Bronger, Holger
    Drecoll, Enken
    Magdolen, Viktor
    Dorn, Julia
    AMERICAN JOURNAL OF CANCER RESEARCH, 2018, 8 (09): : 1856 - 1864
  • [29] Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
    Schoffski, Patrick
    Blay, Jean-Yves
    De Greve, Jacques
    Brain, Etienne
    Machiels, Jean-Pascal
    Soria, Jean-Charles
    Sleijfer, Stefan
    Wolter, Pascal
    Ray-Coquard, Isabelle
    Fontaine, Christel
    Munzert, Gerd
    Fritsch, Holger
    Hanft, Gertraud
    Aerts, Claire
    Rapion, Jerome
    Allgeier, Anouk
    Bogaerts, Jan
    Lacombe, Denis
    EUROPEAN JOURNAL OF CANCER, 2010, 46 (12) : 2206 - 2215
  • [30] Multicenter parallel phase II trials of the polo-like kinase 1 inhibitor BI-2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organisation for Research and Treatment of Cancer (EORTC) Network Of Core Institutes (NOCI)
    Schoeffski, P.
    Blay, J. Y.
    De Greve, J.
    Brain, E.
    Machiels, J. P.
    Soria, S. C.
    Sleijfer, S.
    Munzert, G.
    Rapion, J.
    Lacombe, D.
    EJC SUPPLEMENTS, 2009, 7 (02): : 138 - 139